Perspective Therapeutics (NASDAQ:CATX) Now Covered by Truist Financial

Truist Financial assumed coverage on shares of Perspective Therapeutics (NASDAQ:CATX) in a research report sent to investors on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $12.00 target price on the stock.

Several other brokerages also recently commented on CATX. B. Riley reduced their target price on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. UBS Group decreased their target price on Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $10.00.

Perspective Therapeutics Stock Up 3.8%

Shares of NASDAQ CATX opened at $2.17 on Monday. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $5.39. The company has a market cap of $161.31 million, a P/E ratio of -2.41 and a beta of 1.02.

Perspective Therapeutics Company Profile

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.